Edonentan (BMS 207940) is a highly selective biphenylsulfonamide endothelin A receptor antagonist. (11)C- and (18)F-labeled analogs of edonentan were evaluated of novel PET radioligands for imaging the endothelin-A receptor. Edonentan was in clinical trials for the treatment of heart failure however its development has been discontinued.

Nicopholine is an antitrypanosomal agent.

Nicofurate is a vasodilator, antilipidemic agent.

Neldazosin, a prazosin derivative, is an alpha adrenoreceptor antagonist. It is an antihypertensive substance.

Acetryptine is an antihypertensive agent. Acetryptine was found to bind 5-HT1A and 5-HT1D receptors with high affinity. It may also act as a monoamine oxidase inhibitor (MAOI), specifically, as an inhibitor of MAO-A.

IPROXAMINE is a peripheral vasodilator.

Draflazine is a member of the lidoflazine. Draflazine is a potent inhibitor of equilibrative nucleoside transporters (ENTs). It is more selective for ENT1 relative to ENT2. Draflazine is cardioprotective due to potentiation of receptor-mediated effects of adenosine in the ischemic myocardium. It has also been tested for enhancing cardiac functionality in isolated hearts during storage or transport for transplant operations. Draflazine exhibits overactive bladder activity. It is not yet approved for clinical use.

Dilmefone is a pharmacological agent for increasing capillary wall strength. It was developed as a coronary vasodilator.

Embusartan or BAY106734 (6-n-butyl-4-methoxycarbonyl-2-oxo-1[(2'-(1H-tetrazol-5-yl) -3-fluorobiphenyl-4-yl)methyl] 1,2-dihydropyridine) is an angiotensin II receptors antagonist. Embusartan has beneficial effects in different animal hypertension models. Embusartan appears as a potent and specific new inhibitor of angiotensin II-induced growth-related events in vascular smooth muscle cells. It was being developed for the treatment of hypertension.